The Pharma Data

SEPTEMBER 16, 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Sign up here for the session on Saturday, 19 September, 16:00-16:30 CEST.

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

JANUARY 20, 2021

Morgan Securities LLC, Cowen and Company, LLC and Piper Sandler are acting as joint bookrunning managers for the offering. About CytomX Therapeutics CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies.

Clinical Development 40

Clinical Development Development Sales Antibody 40

The Pharma Data

AUGUST 22, 2021

Two formulations were approved, a tablet and a new oral solution (weight-based dosing). The polyarticular JIA and juvenile PsA approval is based on data from a Phase 3 pivotal study in patients with polyarticular JIA as well as other JIA subtypes, including juvenile PsA. About the JIA Study.

Marketing 52

Marketing Clinical Trials Clinical Trials Development 52

XTalks

AUGUST 2, 2023

In the last quarter of 2021, Pfizer underwent a change in their global structure and now manages their commercial operations through two segments: Biopharma, the innovative biopharmaceutical business, and PC1, their global contract development and manufacturing branch (and lead supplier of active pharmaceutical ingredients).

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

SEPTEMBER 14, 2020

As of July, the company and its federal partner stated that it is on track to supply between 500 million to 1 billion doses a year at a dose of 100 µg now selected for their Phase III trial. Novavax has also tested its recombinant SARS-CoV-2 nanoparticle adjuvanted vaccine in a Phase I/II trial. Novavax’ COVID-19 Vaccine.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92